Article

Integrating Pharmacokinetic, Pharmacogenomic, and Clinical Risk Data to Individualise Hormonal Contraception and Minimise Thrombotic Risk: A Translational Framework.

2026-03-03

Abstract excerpt

Individualizing hormonal contraception requires integrating clinical risk with drug exposure determinants. We performed a comprehensive narrative evidence synthesis combining epidemiology, mechanistic coagulation studies, physiologically‑based pharmacokinetic (PBPK) modelling, drug–drug interaction (DDI) literature and pharmacogenetic reports to clarify how pharmacokinetic and genetic factors alter contraceptive h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c6010189-b38e-5731-98f2-361197198b4e
DOI: 10.22541/au.177251408.89256802/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrating Pharmacokinetic, Pharmacogenomic, and Clinical Risk Data to Individualise Hormonal Contraception and Minimise Thrombotic Risk: A Translational Framework.DOI 10.22541/au.177251408.89256802/v1Read

Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis.Semantic proximity Read

Thrombosis risk with the use of hormonal contraception among women with thrombophilia: An updated systematic review.Semantic proximity Read

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read

Hormonal contraception, thrombosis and age.Semantic proximity Read

Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk.Semantic proximity Read

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.Semantic proximity Read

Oral contraceptives and the risk of thrombosis and atherosclerosis.Semantic proximity Read

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk.Semantic proximity Read

Invited review: Pharmacogenetics of estrogen replacement therapy.Semantic proximity Read

Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk.Semantic proximity Read

When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.Semantic proximity Read

The public health impact of suspending cyproterone acetate/ ethinylestradiol (Diane-35 and generics) in France: A predictive modelling techniqueSemantic proximity Read